Related Experiment Video
Updated: May 2, 2026
04:42
Treating Low Back Pain in Failed Back Surgery Patients with Multicolumn-lead Spinal Cord Stimulation
Published on: June 26, 2018
14.2K
Pharmacologically enhanced spinal cord stimulation for pain: an evolving strategy
1Department of Neurosurgery, Karolinska University Hospital, Sweden.
Pain Management
|March 21, 2014
Summary
Pharmacologically enhanced spinal cord stimulation (SCS) improves treatment for chronic neuropathic pain. Combining SCS with drugs like baclofen shows promise for patients unresponsive to SCS alone.
Area of Science:
- Neuroscience
- Pain Management
- Pharmacology
Background:
- Spinal cord stimulation (SCS) is a key therapy for chronic neuropathic pain.
- A significant percentage of patients (30-50%) show insufficient response to standard SCS.
- Understanding neuronal systems and transmitters involved in SCS is crucial.
Purpose of the Study:
- To review animal data and clinical experience for pharmacologically enhanced spinal cord stimulation.
- To explore the potential of using receptor-active drugs to improve SCS efficacy.
- To assess the current status and future prospects of drug-enhanced spinal stimulation.
Main Methods:
- Review of experimental animal studies on neuronal systems and transmitters in SCS.
- Analysis of clinical trial data for pharmacologically enhanced SCS.
- Summary of clinical experience with adjuvant drugs in SCS.
Main Results:
- Evidence supports intrathecal baclofen as an effective adjuvant to SCS.
- Clinical trials have also investigated clonidine and adenosine in conjunction with SCS.
- Basic studies suggest other pharmacological agents may also enhance SCS therapy.
Conclusions:
- Pharmacologically enhanced spinal cord stimulation represents a novel strategy to improve treatment outcomes for chronic neuropathic pain.
- Intrathecal baclofen has demonstrated relevant data as an adjuvant therapy.
- This field is in its early stages, with potential for future drug-enhanced spinal stimulation therapies.
